• Sarmentosin Drives Autophagy-Dependent Apoptosis in HCC via

  2026-06-04

  This study demonstrates that sarmentosin, a natural product from Sedum sarmentosum, induces autophagy-dependent apoptosis in hepatocellular carcinoma (HCC) by activating Nrf2 and inhibiting mTOR signaling. These mechanistic insights highlight Nrf2 as a promising therapeutic target in HCC and support further exploration of autophagy modulation strategies for overcoming apoptosis resistance in liver cancer.

• Tropifexor (LJN452): Applied FXR Modulation for Barrier Rese

  2026-06-04

  Tropifexor (LJN452) is redefining intestinal epithelial barrier function research by enabling highly selective, reproducible modulation of the FXR signaling pathway. This article delivers concrete workflow guidance, troubleshooting, and advanced protocol tips for leveraging Tropifexor in metabolic and liver disease models, with insights based on recent neonatal piglet and organoid studies.

• SLC25A1 Drives Cisplatin Resistance via H3K27ac-Mediated Sen

  2026-06-03

  Li et al. (2026) demonstrate that SLC25A1 upregulation in head and neck squamous cell carcinoma (HNSCC) enhances cisplatin resistance by promoting cellular senescence through H3K27 acetylation. This mechanistic insight positions SLC25A1 as both a predictive biomarker and a potential therapeutic target for overcoming chemoresistance in HNSCC.

• PF-562271 HCl: Optimizing FAK/Pyk2 Inhibition in Cancer Rese

  2026-06-03

  PF-562271 HCl stands out for its superb selectivity and potency as a FAK/Pyk2 inhibitor, enabling researchers to precisely dissect tumor growth and microenvironmental signaling. This article delivers actionable workflows, evidence-driven troubleshooting, and deep domain integration for advanced cancer research.

• Paroxetine Mesylate: Beyond SSRI – Novel Oncology and Kinase

  2026-06-02

  Explore Paroxetine Mesylate as a selective serotonin reuptake inhibitor with unique multi-kinase and anticancer properties. This article reveals underappreciated assay design considerations and mechanistic advances, setting it apart from conventional overviews.

• RapaLink-1: Third-Generation mTOR Inhibitor for Dormancy and

  2026-06-02

  RapaLink-1 stands out as a third-generation mTOR inhibitor, uniquely enabling both robust tumor suppression and noninvasive induction of embryonic dormancy. This guide details actionable protocols, troubleshooting insights, and comparative advantages for researchers aiming to overcome resistance and achieve precise control of the PIK3CA–AKT–mTOR pathway.

• PF-04971729 (Ertugliflozin): Translational Leverage in Metab

  2026-06-01

  This thought-leadership article for translational researchers offers a mechanistic and strategic exploration of Ertugliflozin (PF-04971729), highlighting its unique selectivity, preclinical and clinical data, and actionable guidance to bridge renal, metabolic, and cardiovascular axes. Integrating evidence from pivotal studies and the latest mechanistic insights, the discussion provides a roadmap for leveraging APExBIO’s Ertugliflozin in advanced diabetes, cardioprotection, and inflammation models.

• Polyethylenimine Linear (PEI), MW 40,000: Optimizing Transfe

  2026-06-01

  Explore how Polyethylenimine Linear (PEI), MW 40,000 elevates DNA transfection efficiency in modern molecular biology. This article uniquely connects mechanistic insight with experimental protocol optimization, informed by new comparative findings.

• Dextrose (D-glucose): Advancing Hypoxia and Immunometabolism

  2026-05-31

  Explore how Dextrose (D-glucose) enables mechanistic insights into tumor hypoxia, metabolic reprogramming, and immunometabolic adaptation. This thought-leadership article bridges the gap between experimental validation and translational strategy, providing protocol parameters, workflow guidance, and a strategic outlook for researchers seeking to unlock the therapeutic potential of glucose metabolism in the tumor microenvironment.

• E-64: Strategic Cysteine Protease Inhibition for Translation

  2026-05-30

  Explore how E-64, a potent L-trans-epoxysuccinyl peptide, is transforming mechanistic research on cysteine proteases. This thought-leadership article navigates the latest findings on cathepsin inhibition, experimental best practices, and translational research strategy—framing E-64’s role in advancing cancer, cell death, and disease modeling applications. With evidence from preclinical studies and expert guidance, we chart a visionary path for integrating E-64 into next-generation workflows.

• AG-490 (Tyrphostin B42): Advanced Modulation of JAK2/STAT6 i

  2026-05-29

  Explore how AG-490 (Tyrphostin B42) enables precise inhibition of the JAK2/STAT6 pathway, advancing cancer immunology and macrophage polarization research. This in-depth article uniquely analyzes assay design, reference breakthroughs, and practical workflow considerations for modern tumor microenvironment studies.

• Localized Muscle BDNF Release Directs Early NMJ Synapse Asse

  2026-05-29

  This study demonstrates that spatially regulated, muscle-generated BDNF release is essential for the initial formation of postsynaptic acetylcholine receptor clusters at vertebrate neuromuscular junctions. By dissecting the trafficking and proteolytic conversion of BDNF—including the role of furin and MMPs—the research provides a mechanistic framework for understanding synaptic assembly and offers actionable points for experimental intervention.

• FLOT1–FOSL2–EphA2 Axis Drives Microglial Polarization in AD

  2026-05-28

  This study uncovers how the interaction between FLOT1 and FOSL2 upregulates EphA2 transcription, activating the p38/MAPK pathway to promote pro-inflammatory microglial polarization in Alzheimer's disease. By disrupting this axis in APP/PS1 mice, researchers observed reduced neuroinflammation and improved cognitive function, highlighting a promising target for therapeutic intervention and the refinement of neurotoxicity models.

• Lopinavir (ABT-378): Optimizing HIV Protease Inhibition Assa

  2026-05-28

  Lopinavir (ABT-378) stands apart for its nanomolar-range potency and exceptional stability in HIV protease inhibition workflows, especially in the presence of serum proteins. This article delivers actionable protocols, troubleshooting strategies, and comparative insights to harness Lopinavir’s capabilities for advanced antiviral and resistance research.

• Naftifine HCl: Allylamine Antifungal Agent for Research Use

  2026-05-27

  Naftifine HCl is a high-purity allylamine antifungal agent that selectively inhibits squalene 2,3-epoxidase, disrupting fungal cell membrane biosynthesis. It is primarily used for topical dermatophytic infections and is supplied for research purposes only. Its robust solubility profile and established purity make it a benchmark for antifungal mechanism studies.

454 records 16/31 page Previous Next First page 上5页 1617181920 下5页 Last page